The Michigan Supreme Court heard oral arguments in a case brought by the state's attorney general against Eli Lilly concerning its insulin pricing. The attorney general's office is seeking the authority to subpoena the drugmaker as part of an investigation into its pricing practices under the Michigan Consumer Protection Act. Eli Lilly has argued that its actions are exempt from this act because they are authorized under federal and state laws governing the sale of insulin. The case reached the state's highest court after lower courts sided with Eli Lilly, denying the attorney general's request for subpoena power. The outcome of this hearing could set a precedent for how pharmaceutical pricing is regulated under state consumer protection laws. An attorney for Eli Lilly argued that the attorney general's investigation is flawed and that the department has not shown any legally viable violation has been alleged.